The Technical Analyst
Celcuity Inc [CELC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Celcuity Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
5.19% $17.24
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 525.01 mill |
| EPS: | -2.69 |
| P/E: | -6.41 |
| Earnings Date: | May 12, 2024 |
| SharesOutstanding: | 30.45 mill |
| Avg Daily Volume: | 0.217 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.41 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.09x |
| Company: PE -6.41 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.286 (-101.66%) $-17.53 |
| Date: 2024-04-20 |
| Expected Trading Range (DAY) |
|---|
|
$ 16.15 - 18.33 ( +/- 6.31%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-08 | Buller Richard E | Buy | 19 558 | Stock Option (right to buy) |
| 2024-04-08 | Buller Richard E | Buy | 12 654 | Stock Option (right to buy) |
| 2024-04-08 | Buller Richard E | Buy | 4 555 | Stock Option (right to buy) |
| 2024-04-08 | Buller Richard E | Buy | 2 310 | Stock Option (right to buy) |
| 2024-04-08 | Buller Richard E | Sell | 19 558 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 9.07 |
| Last 100 transactions |
| Buy: 4 086 807 | Sell: 2 961 758 |
Forecast:
16:00 - $17.24
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $17.24
Forecast 2: 16:00 - $17.24
Forecast 3: 16:00 - $17.24
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $17.24 (5.19% ) |
| Volume | 0.221 mill |
| Avg. Vol. | 0.217 mill |
| % of Avg. Vol | 101.70 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CELC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $14.46 | N/A | Active |
|---|
CELC
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Latest Press Releases
2024-04-04 07:05:00 - Press Release
Celcuity To Present At Upcoming Needham And Stifel Investor Conferences
Minneapolis, april 04, 2024 (globe newswire) -- celcuity inc. (nasdaq: celc), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that brian sullivan, chief executive officer, and co-founder of celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
2024-03-27 16:01:00 - Press Release
Celcuity Inc. Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Corporate Update
Minneapolis, march 27, 2024 (globe newswire) -- celcuity inc. (nasdaq: celc), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the fourth quarter and full year ended december 31, 2023 and other recent business developments.
2024-03-20 07:05:00 - Press Release
Celcuity Inc. Schedules Release Of Fourth Quarter And Full Year 2023 Financial Results And Webcast/conference Call
Minneapolis, march 20, 2024 (globe newswire) -- celcuity inc. (nasdaq: celc), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2023 after the market closes on wednesday, march 27, 2024. management will host a webcast/teleconference the same day at 4:30 p.m. eastern time to discuss the results and provide a corporate update.
2024-03-06 07:05:00 - Press Release
Celcuity To Participate In Leerink Partners Global Biopharma Conference 2024
Minneapolis, march 06, 2024 (globe newswire) -- celcuity inc. (nasdaq: celc), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the leerink partners global biopharma conference 2024 to be held in miami on march 11-13, 2024.
2024-02-28 07:05:00 - Press Release
Celcuity To Participate In Cowen's 44th Annual Health Care Conference
Minneapolis, feb. 28, 2024 (globe newswire) -- celcuity inc. (nasdaq: celc), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in cowen's 44th annual health care conference to be held in boston on march 4-6, 2024.
Latest News
2024-04-04 07:05:00 - GlobeNewsWire
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
2024-03-21 12:21:10 - Zacks Investment Research
Why Celcuity (CELC) Might Surprise This Earnings Season
Celcuity (CELC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2024-03-20 07:05:00 - GlobeNewsWire
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2023 after the market closes on Wednesday, March 27, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
2023-12-01 11:02:00 - GlobeNewsWire
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract accepted for a poster presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS) is now available on the SABCS website. The 2023 San Antonio Breast Cancer Symposium (SABCS) is being held virtually and in-person from December 5-9, 2023.
2023-11-06 07:30:00 - GlobeNewsWire
Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call
MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2023 before the market opens on Monday, November 13, 2023. Management will host a webcast/teleconference the same day at 8:00 a.m. Eastern Time to discuss the results and provide a corporate update.
2023-11-01 07:05:00 - GlobeNewsWire
Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
2023-09-21 16:43:09 - InvestorPlace
The 7 Best Short-Squeeze Stocks to Buy Now: September 2023
The best short-squeeze stocks to buy now can be a perilous territory in the investment landscape. However, they also possess the potential for astronomical returns.
2023-09-06 19:10:05 - InvestorPlace
7 Short-Squeeze Stocks That Actually Might Make Sense
Some of the most speculative ideas are the targeted short-squeeze stocks. To better understand what's going on, it's helpful to think of a timed chess match.
2023-08-03 07:30:00 - GlobeNewsWire
Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call
MINNEAPOLIS, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2023 after the stock market close on Thursday, August 10, 2023. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
2023-05-24 08:00:00 - Accesswire
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
MINNEAPOLIS, MN / ACCESSWIRE / May 24, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in the following investor conferences: One-on-one and small group meetings at the 20th Annual Craig-Hallum Institutional Investor Conference in Minneapolis on Wednesday, May 31, 2023; and A fireside chat at the Jefferies Healthcare Conference in New York at 12:15 p.m. ET on Friday, June 9, 2023.